Biological considerations of plasma-derived and recombinant factor VIII immunogenicity

Abstract excerpt

In hemophilia A, the most severe complication of factor VIII (FVIII) replacement therapy involves the formation of FVIII neutralizing antibodies, also known as inhibitors, in 25% to 30% of patients. This adverse event is associated with a significant increase in morbidity and economic burden, thus highlighting the need to identify methods to limit FVIII immunogenicity. Inhibitor development is regulated by a...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Blood Coagulation and Thrombosis Mechanisms
• Share to Hemophilia Treatment and Research
• Share to Platelet Disorders and Treatments